Jefferies reiterates Keryx at buy

Keryx Biopharmaceuticals, Inc. was reiterated at a buy and a $25 price target by Jefferies & Co., Inc. analyst Adam Walsh. The analyst recommends investors take advantage of the recent sell-off in the company's shares to aggressively build new or add to existing positions. Keryx is down 23% year to date and about 40% off its recent highs. Shares of the New York City-based development-stage company were up $1.10, or 9.78%, at $12.35 on volume of 1,198,042 shares versus the three-month running average of 456,654 shares. (Nasdaq: KERX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.